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Why was the cohort set up?   
Rationale for setting up the cohort 
Type 1 diabetes mellitus (T1DM) affects approximately 0.4-0.5% of the population.  A 70% 
increase in prevalent cases of T1DM in those aged under 15 years in Europe between 2005 
and 2020 is predicted.(1)  T1DM continues to be associated with substantial mortality, with 
an estimated current period life expectancy differential of 11-13 years.(2)  The main chronic 
complications include cardiovascular disease (CVD), nephropathy, retinopathy and 
neuropathy.  CVD risk continues to be increased 2-3 fold relative to the general population 
and diabetic kidney disease remains a major determinant of early mortality in people with 
T1DM.(3) 
 
As detailed in the strategic plans of the main diabetes research funders, research priorities 
include a better understanding of the determinants of T1DM and its complications including 
genetic determinants, improved methods for early detection of complications 
[www.diabetes.org.uk] and the development of sensitive biomarkers for complications 
[www.jdrf.org].  The availability of large prospective cohorts of patients, well characterised 
for complications, is pivotal to such research.  Accordingly, we established the Scottish 
Diabetes Research Network Type 1 Bioresource (SDRNT1BIO) to facilitate a wide range of 
research including, but not limited to the following;  
 
1. Discovery and validation of genetic determinants of type 1 diabetes 
T1DM is partly genetically determined and more than 50 associated genetic loci have been 
identified with the HLA region on chromosome 6 having the major role.(4)  These 
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discoveries yielded insights into the potential pathways causing diabetes some of which are 
now being targeted by novel intervention therapies, however more than 50 known genetic 
loci for T1DM do not explain all the known heritability with estimates of missing heritability 
varying from 20-80%.(5,6)  Among several potential explanations for this “missing 
heritability” are the existence of rare variants with large effects and the existence of 
additional more common variants with effects too low to have been detected by sample 
sizes used so far.  Existing genetic studies of T1DM have been based on around 12000 cases, 
which is many times lower than sample sizes in meta-analyses of genome-wide association 
studies (GWAS) for type 2 diabetes mellitus (T2DM).(4)  Of note, almost all studies to date 
are in cohorts of childhood-onset T1DM, despite the fact that almost 50% of T1DM has its 
onset in adulthood.  The largest study to date of older onset T1DM was limited to evaluation 
of already known loci in 1212 autoantibody positive adults with diabetes in which subtle age 
of onset effects were found for some loci.(7,8)  Thus, additional discovery work to detect 
new T1DM loci is warranted especially for those with older age of onset.  We will conduct 
genome wide association studies using the SDRNT1BIO cohort and a background population 
representative control set of genotypes from Scotland. 
 
2. Discovery and validation of genetic determinants of complications of T1DM 
Many complications of diabetes are heritable (20-50% for retinopathy and nephropathy), 
justifying attempts to discover their genetic determinants.(9)  Few unequivocal replicable 
genetic associations have been found, so large scale initiatives are underway although many 
have greater focus on T2DM than T1DM because of the greater prevalence and larger T2DM 
cohorts [www.imi-summit.eu].  The GENIE Consortium has focused on nephropathy in 
T1DM and a JDRF funded consortium on the genetics of nephropathy in T1DM is currently 
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underway.(10)  For many other phenotypes of relevance in T1DM efforts to discover genetic 
determinants are sparse.  For example, there is little genetic data on neuropathy,(11) 
propensity to hypoglycaemia, or diabetic ketoacidosis.  Thus the GWAS data from the 
SDRNT1BIO will augment existing international efforts to understand the genetics of macro- 
and micro-vascular complications of diabetes and will provide novel GWAS studies of 
neglected traits. 
 
3. Pathogenesis and biomarkers of complications  
Several extremely productive prospective cohort studies of T1DM have yielded much of 
what we know about the pathogenesis and risk factors for complications and how these 
differ between T1DM and T2DM.  These include the EURODIAB PCS (n=2787) (12), the 
Pittsburgh EDC (n=658) (13), the DCCT/EDIC (n=1300) (14), ORPS (n=554) (15), and WESDR 
(n around 1000 (16), CACTI (n around 656) (17), and FinnDiane (n around 4500).(18)  
However, the total sample size and number of incident cases of complications across these 
cohorts does not provide adequate power for discovery efforts.  Larger cohort studies in 
T1DM such as the Swedish National Diabetes Register, use regular reporting of risk factors 
from clinical sites and linkage to routine data but do not currently have any sample 
collection.(19)  To fully exploit new ‘omic methods for pathway and biomarker discovery, 
including lipidomics, metabolomics and genomics, and to develop more precise prediction 
algorithms for complications that incorporate new biomarkers, further large cohorts of 
T1DM patients are needed to supplement these existing excellent cohorts.  With 
SDRNT1BIO, we decided to harness Scotland’s e-health care record system, and the 
existence of a unique health care identifier across all records in Scotland, to enable the 
creation of a cohort in which extensive prospective routine data are automatically captured. 
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4. Stratification of apparent T1DM 
The gold standard biomarker of endogenous insulin production is C-peptide concentrations.  
Previously it was believed that those with T1DM have no residual insulin secretion.  With 
the development of ultra-sensitive C-peptide assays, there is increasing realisation that 
detectable levels of C-peptide are much more common in T1DM than previously 
thought.(20,21,22)  Exploring the genetic and immunological differences between those 
with and without detectable C-peptide might yield possible mechanisms for preserving beta 
cell function and preventing or even reversing T1DM; this is another question being 
addressed by the SDRNT1BIO.(23) 
 
Another aspect of diabetes stratification is the improved detection of maturity onset 
diabetes of the young (MODY) among those misdiagnosed as having T1DM.  Diagnosis of 
MODY remains difficult and at present it is estimated only around 25% of all MODY are 
correctly diagnosed.(24)  The data collected on family history, genotype, C-peptide and 
auto-antibody status, along with sequencing of potential cases, will allow us to compare the 
yield of cases from various detection algorithms. 
 
5. Environmental and socio-economic determinants of T1DM 
The environmental determinants of T1DM remain largely unknown (putative factors include 
infection e.g. congenital rubella, caesarean section, older maternal age, Vitamin D 
deficiency).(25)  Although prospective cohort studies with data pre-dating onset of diabetes 
are an ideal design for examining such factors they are challenging with a disease of 
relatively low incidence such as T1DM.  Nonetheless, the SDRNT1BIO can yield useful 
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information on the role of environment, for example by examining how the pattern of 
potential risk factors varies with genotype or auto-antibody phenotype.  Accordingly we 
have collected some lifestyle, environment and pre-diagnosis data.  For T1DM complications 
the SDRNT1BIO and linked e-health record data is being used to explore socio-economic 
differentials and the impact of health care activities on complications.  
 
Where is it located and how is it funded? 
The SDRNT1BIO was established with joint funding from the Scottish Chief Scientist Office 
and Diabetes UK.  The study activities, including protocol development and recruitment of 
participants, were overseen by a Study Steering Committee including a patient 
representative, the study funders, and lead diabetes consultants from participating Scottish 
Health Boards.  All data and samples (baseline and prospective) are held at the co-
ordinating centre at the University of Dundee, Scotland UK. 
 
 
Who is in the cohort?  
Study Design, Entry criteria and Sampling Frame  
Eligibility criteria are summarised in Table 1.  We aimed to recruit a representative sample 
of all adults aged 16 years and older with a clinical diagnosis of T1DM or with monogenic 
diabetes (i.e. MODY) or with a diagnosis of latent auto-immune disease of adulthood.   
 
The SDRNT1BIO cohort was established using a cross-sectional design for the study 
fieldwork with recruitment primarily focused on 10 of 14 NHS Board regions in Scotland 
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(Table 2).  The Boards not targeted were excluded because of the envisaged high cost per 
participant recruited given the remote geographic location and low population density (i.e. 
the Shetland Orkney and Western Islands and Scottish Borders). 
 
The sampling frame used was the comprehensive SCI-Diabetes electronic health care record 
in which > 99% of patients with diagnosed diabetes are estimated to be registered.  This 
estimate is based on the fact that 99.5% of general practices nationally are electronically 
queried nightly for all records with diagnostic codes for diabetes.  Diagnostic coding levels 
are very high for adults because they are required before practices can receive payments 
under the general practice United Kingdom pay-for-performance program.  Validation 
against other datasets such as hospital admissions with diabetes codes are consistent with 
this > 99% estimate of coverage.(26)  Recruitment was primarily undertaken at diabetes 
outpatient clinics with some additional recruitment in renal units since end stage renal 
disease patients have lower attendance at diabetes clinics.  GP-based clinics were included 
at a few sites of high population density though at present very few people with T1DM in 
Scotland are managed solely in primary care.  At participating clinics we systematically 
evaluated each clinic list for the subsequent week and as many eligible patients, that could 
be seen on the day, were invited to take part on the day or at a subsequent clinic visit.  
There was sufficient research nurse time for 78% (7593/9731) of all attending eligible 
patients to be invited and of these 80.7% (6127/7593) participated.  No financial incentive 
for participation was offered with the exception of travel expenses if a visit outside a routine 
clinic visit was needed. 
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Representativeness  
Tables 3A and 3B show the distribution of some key characteristics among the SDRNT1BIO 
recruits compared to the national population from SCI-Diabetes.  As shown, the participants 
are similar to the national population in almost all characteristics.  With regard to socio-
economic status, 16% of SDRNT1BIO participants are resident in areas with the most 
deprived quintile of Scottish Index of Multiple Deprivation (SIMD) scores (a residential area 
based measure of deprivation) compared to 20% of the total national T1DM population 
(Table 3B).(27) As shown in Table 3B, although we sampled from renal clinics to ensure 
capture of those with end stage renal disease the prevalence of dialysis was 1.2% versus 
1.5% nationally and slightly fewer were albuminuric (11%) compared to the national 
prevalence (19%).  
 
 
What has been measured? 
Baseline data collection took place between 1 December 2010 and 29 November 2013 
inclusive, and comprised a single study visit of approximately 30 minutes.  Informed consent 
was documented for all participants.  Participants were asked to complete a self-report 
questionnaire, and had clinical measures and a blood sample taken.  Additionally patients 
were asked to provide a urine sample at the study visit and were provided a sample tube to 
post back a second urine sample later.  Table 4 summarises the items collected. 
 
Established validated questionnaire instruments were used where these were available.  We 
included the physical activity questions from the International Physical Activity 
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Questionnaire (IPAQ) (28), the Hospital Anxiety and Depression Scale (29), and the widely 
used Michigan Neuropathy Scale.(30)  Acute crises were captured based on reports of 
diabetic ketoacidosis and hypoglycaemic events in the past 12 months and included a 
measure of hypoglycaemic awareness.(31)   
 
For physical examination we captured two blood pressure readings after five minutes of 
sitting quietly, using the OMRON digital BP monitor or equivalent which was validated by 
the British Hypertension Society.  Weight and height were measured using the existing 
scales and stadiometers of each clinic.  Bioimpedance measurements were obtained using 
the Tanita Body Composition Analyser BC-420MA or BC-418MA.  Waist and hip 
measurements were taken using a protocol based on guidance published by the Scottish 
Diabetes Research Network.(32) 
 
Blood samples obtained from participants were processed at the end of each clinic, 
aliquoted and then frozen.  The time elapsed between sampling and freezing at -80oC was 
recorded and the median and interquartile range was 2 h 15 min (1 h 30 min to 3h 10 min).  
Samples were periodically shipped on dry ice to the central laboratory where DNA was 
extracted and samples banked.  
 
 
How often have they been followed up? 
A key aim in setting up the cohort was to harness the potential of data linkage to routine 
electronic health care records as a means of follow up of participants.  Such linkage is 
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feasible in Scotland because the health care records of all patients have a unique health care 
identifier, the Community Health Index (CHI) number.  This is assigned at birth or, for those 
immigrating into Scotland, on registration with a general practitioner (health care is free at 
the point of delivery so almost all residents register with a general practitioner).  All 
SDRNT1BIO participants were consented for such linkage and their study day data have 
been linked to capture both retrospective and prospective data specifically: 
 
1) SCI-Diabetes which captures data on over 99% of patients with diabetes in Scotland and 
contains key clinical encounters for diabetes related care including primary care, 
retinopathy screening, foot screening and issued prescriptions from 2004.  Blood and 
urine test results are also captured, being fed from SCI-Store, a Scotland wide federated 
database from NHS laboratories; 
2) The Scottish Renal Registry which captures data on all those in receipt of renal 
replacement therapy in Scotland since 1960; 
3) Routine data from Information Services Division (ISD) Scotland: 
a) Outpatient attendance (from 1997) 
b) Hospital Inpatient and Day Case Discharges (from 1981) 
c) Birth outcomes including infant mortality and stillbirths (from 1975) 
d) Scottish Cancer Registry data (from 1980)  
e) Deaths (from study day participation onwards). 
 
To date, two linkages have been performed with data coverage up to the end of 2014 for 
the SCI-Diabetes, deaths and cancer linkages and to end 2013 for the others with a further 
linkage pending.  The prospective data linkages are ongoing with annual linkages planned 
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for the foreseeable future.  Participants are considered to have become unobservable if at 
least 1 year has elapsed without any HbA1c measurement or prescription records, or if they 
have been de-registered at their general practice without re-registration there or elsewhere 
in Scotland.  By the end of 2014 it was possible to determine that 118 (1.2%) participants 
were already deceased and of those not deceased 59 persons had no follow up data, 
presumably because of emigration (0.96%).  
 
At recruitment, participants were invited to give consent for future face-to-face follow up, 
to which 93% agreed; as yet we have not taken up this opportunity.  Participants were also 
invited to give consent for having spare blood captured and stored from any future clinical 
encounters, to which 94% of participants agreed.  We have established a mechanism for 
such spare blood capture for the participants in two of the Health Boards and plan to roll 
out this collection nationally as part of the GoSHARE Spare Blood Project 
[http://www.goshare.org.uk/].  To date we hold follow-up EDTA plasma for 300 SDRNT1BIO 
participants.   
 
 
What has it found? Initial findings of interest  
The initial studies using the biosamples of the bioresource are now underway but here we 
describe one useful set of information from the questionnaire data.  Management of T1DM 
has changed in recent years with moves towards more frequent use of basal bolus insulin 
regimens, and pumps, more frequent blood glucose self-testing and carbohydrate counting.  
Here we describe the patterns of insulin management and glucose management among the 
13 
SDRNT1BIO participants and examine associations with gender and socio-economic status.  
Socio-economic status was assessed using the SIMD based on address at time of interview 
divided into quintiles.  Three measures of self-reported insulin and glucose management 
were analysed:  
 
• Insulin Frequency (IF) : < 4 or ≥ 4 injections a day or using pump; 
• Blood Glucose Monitoring (BGM) testing : < 4 or ≥ 4 tests a day; 
• and carbohydrate counting or exchanges (CC) :  yes/no. 
 
Overall 73% (4316) were injecting at least four times daily (IF ≥4) but just 4.6% (269) were 
using a pump (Table 5).  Overall 52% (3055) were testing blood glucose at least four times 
daily (BGM ≥4) and 61% (3552) were using carbohydrate counting or exchange (CC).  Men 
had lower rates than women of IF ≥4 (71% vs. 76%), pump use (2.7% vs 6.9%), BGM ≥4 (48% 
vs 57%), and CC (56% vs 68%).  All measures varied widely by SIMD.  Age-sex adjusted odds 
ratios (OR) (95% CI) per unit increase in SIMD quintile were 1.15 (1.10-1.20) for IF ≥4, 1.32 
(1.20-1.45) for pump use, 1.11 (1.07-1.16) for BGM ≥4, 1.22 (1.17-1.27) for CC, (P=0.001 for 
all) (Table 6).  All three measures (IF, BGM and CC) were associated with lower mean HbA1c 
(Table 7).  HbA1c was lower in those in the more affluent areas (beta regression coefficient 
per SIMD quintile -0.17 (95% CI -0.20,-0.14), P=0.0001 adjusted for age and sex, beta -0.14 
(95% CI -0.17,-0.11) on adjustment for glucose management).  We conclude that structured 
patient education programmes aimed at improving self-management, as recommended in 
our national diabetes strategy, need to explicitly tackle inequalities by sex and deprivation. 
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What are the main strengths and weaknesses? 
The main strengths of the SDRNT1BIO cohort are: (i) its large size; (ii) the comprehensive 
retrospective and prospective capture of a wide range of health data; (iii) the large set of 
biosamples obtained; (iv) that the cohort is being comprehensively genotyped; (v) its broad 
representativeness of the national adult population with T1DM; (vi) the high rate of consent 
to future follow up; (vii) the high rate of consent to spare blood capture; and (viii) the low 
cost of the work given the amount of data collected.  Weaknesses are that: (i) only a subset 
have follow-up biosamples as yet; (ii) lack of funding to date for re-examination; and (iii) 
need to improve discoverability and infrastructure support for collaborative use. 
 
 
Can I get hold of the data? Where can I find out more? 
The study was carried out in accordance with the ethical principles in the Declaration of 
Helsinki and was approved by the Tayside Research Ethics Committee (Reference 
10/S1402/43).  Biosamples are held under the governance of the Tayside Tissue Bank.  Data 
linkages are approved by the National Caldicott Guardians (References: 2013/009; 
2013/0014), Public Benefit and Privacy Panel for Health and Social Care (Reference 15/13), 
NHS Central Register (NHSCR), and the Scottish Renal Registry. 
 
The SDRNT1BIO was established to support collaborative research use.  We aim to achieve 
the appropriate balance between fostering use and maintaining the data governance and 
security of linked data.  All data are held in an anonymised form with the file linking study 
identifier to identifiable patient details held separately and unavailable to researchers.  Data 
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are held on a secure server accessible only to approved researchers.  Analysis takes place on 
the server with access via end-to-end encrypted secure shell tunneling.  Analysts must have 
undertaken an approved data security course.  A data access committee oversees 
applications for collaboration.  Criteria for approval include having a scientifically justified 
question, the feasibility and power to address the question in the dataset, whether the 
question is already being examined using the data, whether the application is a bone fide 
researcher in a research institution and whether exhaustible material is being requested.  
Samples are not issued externally but application can be made to have specified funded 
measures made if these are scientifically valid and if the question exploits the unique 
characteristics of the cohort (i.e. cannot be examined in a less extensive resource).  In 
person follow up studies cannot be initiated by external collaborators for privacy reasons 
but can be proposed as collaborations.  
 
To date biosamples have been used for DNA extraction and genome wide genotyping.  
Serum samples have been used for the measurement of C-peptide, serum creatinine, auto-
antibodies (GAD, ZnT8, IA2) and for N-glycome analysis.(33)  The results of these are 
awaited.  Urine samples have been used for measurement of albumin:creatinine ratio.  
These studies represent collaborations with researchers in the United States, Croatia, 
Finland, Scotland, and the rest of the United Kingdom.  Interested collaborators should 
contact the study coordinator in the first place for access forms 
[Helen.Colhoun@igmm.ed.ac.uk]. 
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Profile in a nutshell 
 The SDRNT1BIO is one of the largest and most comprehensive collections of 
biomaterials from people with type 1 diabetes (T1DM) in existence, and has been 
shown to be representative of the national adult population with T1DM. 
 6,127 adults, aged 16 years or older, with T1DM were recruited from across Scotland 
between 01/12/2010 and 29/11/2013 with a high rate of consent to future follow 
up. 
 Biosamples include baseline collections of serum, plasma, whole blood and urine 
alongside follow-up capture of plasma where patients consented to spare blood 
capture. 
 Baseline data includes sociodemographics, details of diabetes diagnosis and 
treatment, history of complications and lifestyle assessment e.g. physical activity, 
smoking and alcohol aspects, alongside results from physical measures e.g. 
anthropometry, bioimpedance, and blood pressure. 
 Data linkage to routine electronic health care records has allowed retrospective and 
prospective data capture across a number of health outcomes including diabetes 
related care in primary care, renal replacement therapy, outpatient attendance, 
hospitalizations, cancers and deaths.  The SDRNT1BIO has also been 
comprehensively genotyped. 
 SDRNT1BIO was established to support collaborative research use; access forms are 
available from the study coordinator [Helen.Colhoun@igmm.ed.ac.uk]. 
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Title:  Cohort Profile:  Scottish Diabetes Research Network Type 1 
Bioresource Study (SDRNT1BIO) 
 
Table 1. Inclusion and exclusion criteria for participation in SDRNT1BIO cohort 
Inclusion criteria main study 
(1) Male or female 
(2) 16 years of age or over 
(3) Not currently pregnant 
(4) Able to give informed consent 
(5) A label of type 1 diabetes (T1DM), MODY or LADA on SCI-DC database or in 
clinical record 
(6) Interval between diagnosis and starting insulin <1 year for patients with 
diagnosis of T1DM 
(7) Current use of insulin if diagnosed with T1DM 
 
Exclusion criteria for main study and MODY sub-study 
(1) Known secondary basis for diabetes e.g. haemochromatosis, pancreatitis, 
pancreatectomy  
MODY, maturity onset diabetes of the young; LADA, latent autoimmune diabetes in adults 
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Table 2. Health Boards in order of contribution to Scottish-wide population with T1DM 
 Type 1 Bioresource 
participants (N=6127) 
National T1DM 
population (N= 24552) 
 N, percent (SE) N, percent (SE) 
Greater Glasgow & Clyde 949, 15.50 (0.014) 5327, 21.70 (0.003) 
Lothian 1592, 26.00 (0.012) 3900, 15.89 (0.003) 
Lanarkshire 407, 6.65 (0.015) 2816, 11.47 (0.004) 
Grampian 749, 12.23 (0.014) 2679, 10.91 (0.004) 
Ayrshire & Arran 113, 1.85 (0.016) 1782, 7.26 (0.004) 
Fife 699, 11.41 (0.014) 1759, 7.16 (0.004) 
Tayside 937, 15.30 (0.014) 1716, 6.99 (0.004) 
Highlands 176, 2.87 (0.016) 1481, 6.03 (0.004) 
Forth Valley 243, 3.97 (0.016) 1453, 5.92 (0.004) 
Dumfries & Galloway 231, 3.77 (0.016) 737, 3.00 (0.004) 
Borders 18, 0.29 0.016) 512, 2.09 (0.004) 
Western Isles, Orkney and Shetland 12, 0.20 (0.001) 390, 1.59 (0.001) 
SE, standard error. 
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Table 3A A Comparison of SDRNT1BIO participants with national Scottish population with Type 1 Diabetes (continuous variables) 
Characteristic Type 1 Bioresource participants (N=6127) National T1DM population (N=24552) 
N, mean (SD) 
Median 
(25th,75th percentile) 
N, mean (SD) 
Median 
(25th,75th percentile) 
Age at entry, y 6127, 44.8 (14.8) 45.1 (33.1,55.5) 24552, 43.3 (15.6) 42.9 (30.9,53.9) 
Diabetes duration, y 6127, 21.5 (13.5) 20.2 (10.8, 31.0) 24552, 20.7 (13.1) 18.9 (10.4,29.8) 
Age at diagnosis, y 6127, 23.3 (14.1) 22.3 (12.0,32.0) 24552, 22.6 (13.3) 21.0 (12.1,31.0) 
HbA1c, mmol/mol 6103, 71.4 (16.9)] 69.0 (60.0,80.0) 22318, 73.1 (19.2) 70.3 (60.7,83.0) 
MDRD eGFR, ml/min/1.73m2 5752, 89.2 (24.5) 88.7 (74.2,103.5) 20909, 89.1 (26.5) 88.3 (73.4,104.2) 
Systolic blood pressure, mmHg 6094, 130.1 (16.9) 129 (119,140) 22515, 129.3 (17.1) 129 (118,140) 
Diastolic blood pressure, mmHg 6094, 75.0 (10.2) 75 (68, 82) 22513, 74.6 (10.1) 75 (68,80) 
BMI, kg/m2 5637, 26.9 (4.6) 26.3 (23.7, 29.5) 21674, 27.1 (5.5) 26.4 (23.4,30.0) 
S, standard deviation; y, years; MDRD, Modification of Diet in Renal Disease, eGFR = 186 x (creatinine in mmol/l/88.4)-1.154 x (age-0.203) x 0.742 (if female) x 
(1.210 if black), 
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Table 3B. Comparison of SDRNT1BIO participants with national Scottish population with 
Type 1 Diabetes (categorical variables) 
Characteristic Type 1 Bioresource 
participants (N=6127) 
National T1DM 
population (N=24552) 
N, percent (SE) N, percent (SE) 
Female sex 2696, 44.0 (0.009) 10718, 43.7 (0.002) 
Diabetes duration ≥ 5 y 5440, 88.8 (0.002) 21793, 88.8 (0.000) 
Diabetes diagnosed at age 50 y 308, 5.03 (0.016) 892, 3.6 (0.004) 
Known MODY 29, 0.47 (0.016) N/A 
Known LADA 4, 0.07 (0.016) N/A 
SIMD quintile   
  1 (most deprived) 956, 15.8 (0.014) 4750 , 20.0 (0.003) 
  2 1021, 16.8 (0.014) 4807 , 20.3 (0.003) 
  3 1158, 19.1 (0.013) 4932, 20.8 (0.003) 
  4 1369, 22.6 (0.013) 4723, 19.9 (0.003) 
  5 (least deprived) 1562, 25.8 (0.012) 4515, 19.0 (0.003) 
History of diabetes related 
complications 
  
  Any retinopathy ever 4681, 77.4 (0.004) 17862, 77.1 (0.001) 
  Retinopathy at most recent screening 3832, 63.4 (0.006) 12777 , 55.1 (0.002) 
  Cardiovascular disease admission 473, 7.7 (0.015) 2212, 9.0 (0.004) 
  Ever received dialysis 73, 1.2 (0.016) 363, 1.5 (0.004) 
Albuminuric status   
  Normoalbuminuric 4605, 88.6 (0.002) 17578, 81.4 (0.001) 
  Microalbuminuric 449, 8.6 (0.018) 3196, 14.8 (0.004) 
  Macroalbuminuric 141, 2.7 (0.019) 823, 3.8 (0.004) 
Albuminuric status based on 
SDRNT1BIO samples (≥ 1 ACR reading) 
5839, 95.3 (0.00)  
SE, standard error of mean;  ACR, urine albumin to creatinine ratio; y, years; N/A, not applicable. 
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Table 4. Summary of SDRNT1BIO baseline measures (2011-13) 
Measure Variables 
Self-report 
questionnaire 
Demographic characteristics 
• Date of birth 
• Sex 
• Ethnicity 
• Location when diabetes diagnosed 
Family History of diabetes 
Diabetes & Clinical History 
• Date of diagnosis 
• Other health conditions including specific questions on 
coeliac, rheumatoid and other auto-immune conditions 
Glucose and Insulin management 
• Start of insulin therapy and current regime 
• Date insulin injections started 
• Current insulin dose 
• Carbohydrate counting/exchange 
• Glucose self-monitoring 
Diabetes acute crises 
• Ketoacidosis 
• Hypoglycaemia 
History of diabetes complications 
• Kidney dialysis/transplant 
• Laser therapy to back of the eye 
• Amputation 
• Complications affecting legs and/or feet 
• Diabetic neuropathy diagnosis  
• Michigan neuropathy scale  
• Hospital Anxiety and Depression Scale (HADS) – 14 items 
Lifestyle 
Alcohol units per week  
Smoking habits (cigarettes/cigars/pipes) 
• Current smoker, ex-smoker, non-smoker 
• Frequency/number times a day smoked 
• Age started to smoke 
Physical activity  
• Intensity over previous week: vigorous, moderate, 
walking, sitting 
• Duration of activity over previous 7 days 
• Typical daily duration (hours and minutes) 
Clinical 
measures 
Sitting Blood pressure 
Height  
Weight  
Waist-hip ratio 
Bioimpedence 
28 
Biosamples 
stored 
Blood – non-fasting (n=6005 persons with a sample) 
• Serum, Plasma, whole blood in EDTA, whole blood in 
Paxgene tubes  
Single urine sample (n=5839 persons with a sample) 
Two urine samples (n=4902 persons with two or more samples) 
 
 
 
 
Table 5. Glucose management measures by age (years) and sex 
 Males     
 16-24 25-49 50-74 ≥ 75 All ages 
n 344 1809 1214 64 3431 
HbA1c, mmol/mol 77.3 (1.2) 71.94 (0.4) 68.4 (0.4) 66.8 (1.7) 71.1 (0.3) 
Insulin Frequency ≥4 
injections/day 
254 (78.9) 1330 (76.3) 743 (63.7) 21 (35.0) 2348 (71.3) 
Insulin pump use 11 (3.4) 42 (2.4) 37 (3.2) 0 (0) 90 (2.7) 
Blood glucose 
Monitoring ≥4 
tests/day 
124 (38.6) 832 (47.9) 589 (50.5) 27 (44.3) 1572 (47.9) 
Carbohydrate 
counting 
181 (56.4) 983 (56.8) 616 (54.1) 30 (50.0) 1810 (55.7) 
 
 Females 
    
 
16-24 25-49 50-74 ≥ 75 All ages 
 
N 302 1413 919 62 2696 
HbA1c, mmol/mol 82.4 (1.3) 72.8 (0.5) 71.0 (0.5) 69.9 (1.9) 73.2 (0.4) 
Insulin Frequency ≥ 4 
injections/day 
233 (79.3) 1078 (79.0) 624 (71.4) 33 (54.1) 1968 (75.9) 
Insulin pump use 18 (6.1) 115 (8.4) 46 (5.3) 0 179 (6.9) 
Blood glucose 
Monitoring ≥ 4 
tests/day 
151 (51.2) 775 (56.9) 519 (59.7) 38 (62.3) 1483 (57.3) 
Carbohydrate 
counting 
189 (64.3) 964 (70.7) 568 (66.5) 21 (36.2) 1742 (67.8) 
Data shown are mean and standard error for HbA1c, and numerator (%) for the other measures. 
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Table 6.  Odds of glucose management measures according to the Scottish Index of Multiple 
Deprivation 
Indicator 
Quintile of Scottish Index of Multiple 
Deprivation 
Least versus 
most deprived 
1 (most 
deprived) 
2 3 4 
5 (least 
deprived) 
OR (95% CI) 
Insulin frequency ≥ 
4 injections/day 
612 (67.8) 
681 
(70.3) 
808 
(73.1) 
1012 
(76.3) 
1156 
(75.9) 
1.48 (1.26,1.72) 
Insulin pump use 13 (1.4) 
30 
(3.1) 
53 
(4.8) 
87 
(6.6) 
81 (5.3) 4.08 (2.33, 7.73) 
Blood glucose 
Monitoring ≥ 4 
tests/day 
408 (45.6) 
464 
(48.0) 
572 
(51.9) 
715 
(54.0) 
864 (56.6) 1.53 (1.29,1.81) 
Carbohydrate 
counting 
422 (47.2) 
543 
(56.9) 
687 
(63.1) 
866 
(65.8) 
997 (66.1) 2.31 (1.94,2.74) 
Data are numerator (%) unless otherwise indicated; odds ratio adjusted for age and sex, P < 0.001 
for all indicators. 
 
 
 
Table 7.  HbA1c in mmol/mol by glucose management measures 
Indicator Yes 
Mean (SE) 
No 
Mean (SE) 
Age-sex 
adjusted  
P-value 
Insulin frequency ≥ 4 injections/day 71.8 (0.1) 72.1 (0.2) <0.001 
Insulin pump use 64.8 (0.8) 72.2 (0.3) <0.001 
Blood glucose Monitoring ≥ 4 tests/day 69.3 (0.3) 74.6 (0.4) <0.001 
Carbohydrate counting 70.8 (0.3) 73.4 (0.4) <0.001 
SE= standard error. 
 
